Connect with us

Business

What to know about the Pfizer vaccine – CTV News

Published

 on


PARIS, FRANCE —
Reports that one of the vaccines for COVID-19 has shown highly promising results are a ray of hope for a world in the shadow of surging virus cases.

But does it mean the pandemic is coming to an end? Not so fast, experts say, with many questions remaining about who it will protect and for how long.

On Monday American pharmaceutical giant Pfizer and its German partner BioNTech said that their vaccine candidate has been 90 per cent effective in preventing COVID-19 infections in ongoing Phase 3 trials.

One of dozens in development, it is based on innovative technology that has never been approved for use before.

While its apparent efficacy sparked intense excitement, with only partial data so far released, we don’t yet know how long it will last, whether it will protect the most vulnerable and how it could be distributed across the world.

90 PER CENT

Pfizer and BioNTech are basing their announcement on interim results from the last step in their clinical trial before making an application for approval.

They said that the vaccine was found to be “more than 90 per cent effective” in preventing participants from being infected.

This was based on 94 COVID-19 cases being found at this stage in the trial, which has enrolled 43,538 people.

But the announcement does not break down those figures to show how many infected patients were in the group that received the vaccine and how many were in the one that was given a placebo.

This points to the deeper issue that the results were distributed in a press release — sending stock markets surging — rather than in a detailed peer reviewed paper in a scientific journal.

“These results are extremely interesting,” said French virologist Marie-Paule Kieny, who leads research at Inserm and is a former director at the World Health Organisation.

“But we need to wait to see the data, which is not yet available,” she told AFP.

Other data is still being collected, notably on safety, although the firms said “no serious safety concerns” have been raised.

LONG-TERM PROTECTION?

Another unknown is how long the vaccine’s protection may last.

Effectiveness was measured seven days after patients received the final injection of the two-dose vaccine, 28 days after the initial jab.

This means we cannot yet know the duration of protection, Penny Ward, Visiting Professor in Pharmaceutical Medicine at King’s College London, told the Science Media Centre.

“Longer periods of follow up are required during an ongoing outbreak to determine need for repeated booster doses.”

With a view to possible authorisation by the United States Drug Agency (FDA), the two companies have indicated they will also publish results measured 14 days after the second injection.

Bruno Pitard, of France’s CNRS national scientific research centre, told AFP that one of the challenges is knowing how the effectiveness of the vaccine changes over time.

“After three weeks, then a month, then two, then three, then four, we will see if the protection is still the same,” he said.

WHAT DOES IT DO?

Does this vaccine stop people from catching COVID-19, or does it just reduce the severity of their symptoms? And can it prevent someone from spreading the virus?

There is no published data to tell us either way.

This is a crucial point, said Ward, because if a vaccine can protect against infections then we could theoretically ease the restrictive measures put in place to halt the virus’ spread.

If, however, it mainly reduces the risk of disease but not infection, then restrictions would be needed “until sufficient numbers of individuals have been vaccinated to protect those at most risk of needing hospital care or of dying from disease from becoming very unwell by catching the infection from a vaccinated, asymptomatically infected person.”

WHO DOES IT PROTECT?

After ten months we have a better idea of who those most at risk are.

Older people, men and those who have obesity, diabetes or hypertension are among those more likely to develop serious illness.

But Pfizer and BioNTech do not reveal whether their vaccine is effective for these vulnerable groups.

“In scientific publications, we see stratification of individuals, according to their age, the presence of comorbidities (underlying medical conditions), ethnic origin, etc,” said Pitard.

“Here we have none of that.”

WHO CAN HAVE IT?

The vaccine developed by Pfizer and BioNTech — along with another vaccine from U.S. firm Moderna — involves injecting the body with strands of genetic instructions called “messenger RNA”, which tell our cells how to fight the coronavirus.

One significant downside to these new messenger RNA vaccines is they must be stored at very low temperatures — in this case -70 degrees Celsius — although it can be kept in the fridge for up to five days.

The very low storage temperatures could pose a particular problem for poorer nations in the Global South, said Toby Peters, Professor of Cold Economy at the University of Birmingham.

“Nowhere on the planet does the logistical capacity exist to distribute vaccines at this temperature and volume without massive investment,” he said, adding that “we cannot allow this to become, by default, a divided solution” between haves and have-nots.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Housing growth, auto loans drive up demand for credit in third quarter: Equifax – Business News – Castanet.net

Published

 on


Consumer demand for credit intensified in the third quarter, driven chiefly by increases in mortgage balances and new auto loans, according to data released Monday by credit reporting agency Equifax.

Mortgage balances and new auto loans were up 6.6 per cent and 11.7 per cent year over year, respectively, according to Equifax. Overall average consumer debt increased 3.3 per cent compared with the third quarter of last year.

Rebecca Oakes, assistant vice-president of advanced analytics at Equifax Canada, said in an interview that growth in mortgages last quarter was especially high, with the largest increase among people under 35. That trend comes even as economic fallout from the pandemic and associated lockdown measures hit young people especially hard.

“In terms of new mortgages, that could be refinancing, or it could be brand-new, first-time homebuyers or it could be people moving house,” Oakes said. “That was actually the highest value that we’ve seen ever.”

The increased demand for auto loans in the third quarter could have been a result of pent-up demand from people who had to wait to buy cars later in the year, Oakes said.

The figures in Equifax’s report are drawn from banks and other lenders that provide data to the credit rating agency.

Equifax pegged total consumer debt at $2.04 trillion, while Statistics Canada reported in June that household debt had reached $2.3 trillion, with $1.77 in debt for every dollar of household disposable income.

More than three million consumers have chosen to use payment deferral programs since the start of the COVID-19 pandemic, according to Equifax. Since the start of this year, some banks have offered consumers the option to suspend their loan payments for several months, in recognition of the financial strain the pandemic has created for many households.

However, under the payment deferral programs, interest continues to accrue during the months for which payments are suspended.

The percentage of balances where credit users have missed three or more payments was at its lowest level since 2014, with deferral programs likely masking the true delinquency rates, according to Oakes.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Housing growth, auto loans drive up demand for credit in third quarter: Equifax – Business News – Castanet.net

Published

 on


Consumer demand for credit intensified in the third quarter, driven chiefly by increases in mortgage balances and new auto loans, according to data released Monday by credit reporting agency Equifax.

Mortgage balances and new auto loans were up 6.6 per cent and 11.7 per cent year over year, respectively, according to Equifax. Overall average consumer debt increased 3.3 per cent compared with the third quarter of last year.

Rebecca Oakes, assistant vice-president of advanced analytics at Equifax Canada, said in an interview that growth in mortgages last quarter was especially high, with the largest increase among people under 35. That trend comes even as economic fallout from the pandemic and associated lockdown measures hit young people especially hard.

“In terms of new mortgages, that could be refinancing, or it could be brand-new, first-time homebuyers or it could be people moving house,” Oakes said. “That was actually the highest value that we’ve seen ever.”

The increased demand for auto loans in the third quarter could have been a result of pent-up demand from people who had to wait to buy cars later in the year, Oakes said.

The figures in Equifax’s report are drawn from banks and other lenders that provide data to the credit rating agency.

Equifax pegged total consumer debt at $2.04 trillion, while Statistics Canada reported in June that household debt had reached $2.3 trillion, with $1.77 in debt for every dollar of household disposable income.

More than three million consumers have chosen to use payment deferral programs since the start of the COVID-19 pandemic, according to Equifax. Since the start of this year, some banks have offered consumers the option to suspend their loan payments for several months, in recognition of the financial strain the pandemic has created for many households.

However, under the payment deferral programs, interest continues to accrue during the months for which payments are suspended.

The percentage of balances where credit users have missed three or more payments was at its lowest level since 2014, with deferral programs likely masking the true delinquency rates, according to Oakes.

Let’s block ads! (Why?)



Source link

Continue Reading

Business

Stock market news live updates: Dow falls, but heads toward best month in more than three decades – Yahoo Canada Shine On

Published

 on


GlobeNewswire

Biological Seed Treatment Market to be worth USD 2,037.5 Million By 2027 | Reports and Data

The rising demand in the agricultural sector for food grains and the scarcity of arable lands are driving the demand for the Biological Seed Treatment market.New York, Nov. 30, 2020 (GLOBE NEWSWIRE) — The Global Biological Seed Treatment Market is forecast to reach USD 2,037.5 million by 2027, according to a new report by Reports and Data. Rising demand in the agriculture sector for food grains and growing R&D to increase crop yield and seed potential is expected to drive the growth of the biological seed treatment market. The growing focus on organic farming in the agricultural sector is most likely to fuel the demand for biological seed treatment over the forecast period. The escalating need to enhance plant nutrients’ availability in the root system is boosting the demand for biological seed treatment solutions. The increasing awareness pertaining to the adverse effects of chemical seed treatment among health-conscious consumers is furthering the utilization of biological seed treatment solutions.The high cost associated with biological seed treatments and the lack of awareness among farmers regarding sustainable agricultural practices is restricting the growth of the biological seed treatment market over the forecast period.  Get FREE Sample Copy with TOC of the Report to understand the structure of the complete report@ https://www.reportsanddata.com/sample-enquiry-form/3696Further key findings from the report suggest * The increasing demand in the agricultural sector for food grains and scarcity of arable lands are driving the growth of the market. The increase in awareness among consumers regarding the environment and health has propelled the market growth. * The government of several countries has restricted the use of chemical pesticides and is encouraging biological seed treatment products. They are taking initiatives for promoting biological seed treatment products and awarding grants for the research and development of seed treatment products. * The Asia Pacific market is expected to grow at a CAGR of 12.4% over the forecast period, making it the fastest-growing region in the biological seed treatment market. There is a significant demand for biological seed treatment in the region for the minimization of the usage of excessive pesticides. * The biological seed treatment market is adopting some wiser strategies in order to say competitive between the growing demand for the products. Prominent brands in the sector have undertaken collaborations to expand their product portfolios and enter new markets. To retain the position of products in the competitive market, companies are adopting effective marketing and branding strategies. * Key participants include BASF SE, Syngenta International AG, Bayer CropScience AG, DuPont, Monsanto Company, Koppert Biological Systems, ADAMA agricultural solutions, Plant Health Care, Incotec, and Verdesian Life Sciences, among others.  BUY NOW (Customized Report Delivered as per Your Specific Requirement)@ https://www.reportsanddata.com/checkout-form/3696For the purpose of this report, Reports and Data has segmented the Global Biological Seed Treatment Market on the basis of product, function, crop type, and region: * Product Outlook (Revenue, USD Million; 2017-2027) * Botanicals & others * Microbials (Fungi, Bacteria) * Function Outlook (Revenue, USD Million; 2017-2027) * Seed Enhancement (Biostimulants, Biofertilizers) * Seed Protection (Biofungicides, Bioinsecticides) * Crop Type Outlook (Revenue, USD Million; 2017-2027) * Wheat * Corn * Sunflower * Cotton * Soybean * Vegetable crops * OthersTo identify the key trends in the industry, click on the link below:   https://www.reportsanddata.com/report-detail/biological-seed-treatment-market * Regional Outlook (Revenue, USD Million; 2017-2027) * North America 1. U.S. 2. Canada * Europe 1. Germany 2. U.K. 3. France 4. BENELUX 5. Rest of Europe * Asia Pacific 1. China 2. Japan 3. South Korea 4. Rest of APAC * MEA 1. Saudi Arabia 2. U.A.E. 3. Rest of MEA * Latin America 1. Brazil 2. Rest of LATAMTake a Look at our Related Reports:Natural Rubber Market Analysis by Product Type (RSS Grade, Latex Concentrate, Solid Block), Distribution Channel (Online, Offline), Application (Automobiles, Gloves, Footwear) and Region – Forecast To 2027Digital Farming Market Size, Share & Analysis, By Component (Hardware, Software, And Others), By Application (Precision Farming, Live Stock Monitoring, Green House Farming, And Others) And By Region – Forecasts To 2027Ornamental Fish Market By Types (Cold-water Fish, Tropical Fish) By Applications (Commercial Application, Residential Application) Forecast 2020 To 2027Fishing Nets and Aquaculture Cages Market By Type (Fishing Nets, Aquaculture Cages) By Application (Individual Application, Commercial Application) Regional Outlook And Forecasts, 2020-2027Dripline Market By Type (PC Dripline, Non-PC Dripline, Others), By Application (Farms, Commercial Greenhouses, Residential Gardeners, Others) And Region- Global Forecasts To 2027About Reports and DataReports and Data is a market research and consulting company that provides syndicated research reports, customized research reports, and consulting services. Our solutions purely focus on your purpose to locate, target and analyze consumer behavior shifts across demographics, across industries and help client’s make a smarter business decision. We offer market intelligence studies ensuring relevant and fact-based research across a multiple industries including Healthcare, Technology, Chemicals, Power, and Energy. We consistently update our research offerings to ensure our clients are aware about the latest trends existent in the market. Reports and Data has a strong base of experienced analysts from varied areas of expertise.Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370E-mail: sales@reportsanddata.comLinkdIn | Twitter | BlogsLinkdIn | Twitter | BlogsRead Full Press Release@ https://www.reportsanddata.com/press-release/global-biological-seed-treatment-market CONTACT: Contact Us: John W Head of Business Development Reports And Data | Web: www.reportsanddata.com Direct Line: +1-212-710-1370 E-mail: sales@reportsanddata.com LinkdIn | Twitter | BlogsLinkdIn | Twitter | Blogs

Let’s block ads! (Why?)



Source link

Continue Reading

Trending